
	U.S. dialysis		Other - Ancillary services		Consolidated
Balance at December 31, 2023	$	6,416,825	$	695,735	$	7,112,560
Acquisitions	102,082		246,987		349,069
Divestitures	(1,687)		(1,506)		(3,193)

Foreign currency and other adjustments	—		(83,220)		(83,220)
Balance at December 31, 2024	$	6,517,220	$	857,996	$	7,375,216
Acquisitions	10,396		61,288		71,684


Foreign currency and other adjustments	—		98,195		98,195
Balance at December 31, 2025	$	6,527,616	$	1,017,479	$	7,545,095

Balance at December 31, 2025:
Goodwill	$	6,527,616	$	1,174,220	$	7,701,836
Accumulated impairment charges	—		(156,741)		(156,741)
	$	6,527,616	$	1,017,479	$	7,545,095

Substantially all of the Company’s operating segments described in Note 24 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.

Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.

The Company has applied a similar aggregation to the dialysis centers within each of its international reporting units. For the Company’s other operating segments, discrete business components below the operating segment level constitute individual reporting units.

The Company performed various annual impairment assessments during the year ended December 31, 2025 and 2024, with no impairment indicated. None of the Company’s reporting units were considered at risk of significant goodwill impairment as of December 31, 2025.

During the year ended December 31, 2023, the Company performed its annual impairment assessment of its transplant software reporting unit and recognized a goodwill impairment charge of $26,083 in that reporting unit, or $19,575 net of tax. This charge resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving

its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate. After this impairment charge, the transplant software reporting unit had a goodwill balance of $14,424 remaining.